Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

Bristol-Myers Squibb Co DRC (BMYm)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
20,525.00 -450.00    -2.15%
16:04:59 - Delayed Data. Currency in ARS ( Disclaimer )
Type:  Equity
Market:  Argentina
ISIN:  ARDEUT112877 
  • Volume: 356
  • Bid/Ask: 20,525.00 / 20,600.00
  • Day's Range: 20,525.00 - 21,250.00
Bristol-Myers Squibb DRC 20,525.00 -450.00 -2.15%

BCBA:BMYm Financials

 
A brief overview of the BCBA:BMYm financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Bristol-Myers Squibb over time.

Bristol-Myers Squibb Company reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 276 million compared to USD 309 million a year ago. Revenue was USD 12,201 million compared to USD 11,226 million a year ago. Net income was USD 1,680 million compared to USD 2,073 million a year ago. Basic earnings per share from continuing operations was USD 0.83 compared to USD 0.99 a year ago. Diluted earnings per share from continuing operations was USD 0.83 compared to USD 0.99 a year ago.For the six months, sales was USD 582 million compared to USD 598 million a year ago. Revenue was USD 24,066 million compared to USD 22,563 million a year ago. Net loss was USD 10,231 million compared to net income of USD 4,335 million a year ago. Basic loss per share from continuing operations was USD 5.05 compared to basic earnings per share from continuing operations of USD 2.07 a year ago. Diluted loss per share from continuing operations was USD 5.05 compared to diluted earnings per share from continuing operations of USD 2.06 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

BMYm Income Statement

Gross margin TTM 76.18%
Operating margin TTM 19.42%
Net Profit margin TTM -14.06%
Return on Investment TTM 10.54%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 12201 11865 11477 10966
Gross Profit 9230 8955 8770 8476
Operating Income 2598 2284 1952 2104
Net Income 1680 -11911 1762 1928

BMYm Balance Sheet

Quick Ratio MRQ 0.79
Current Ratio MRQ 1.16
LT Debt to Equity MRQ 287.15%
Total Debt to Equity MRQ 317.39%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 94646 99031 95159 91263
Total Liabilities 77577 82483 65674 62201
Total Equity 17069 16548 29485 29062

BMYm Cash Flow Statement

Cash Flow/Share TTM 6.99
Revenue/Share TTM 22.94
Operating Cash Flow  10.00%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 2326 2834 4252 4751
Cash From Investing Activities -1319 -19618 -1346 -410
Cash From Financing Activities -4023 14644 967 -5160
Net Change in Cash -3038 -2185 3951 -857
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BMYm Comments

Write your thoughts about Bristol-Myers Squibb Co DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email